| Literature DB >> 26273358 |
Guojin Wang1, Yuanguo Wang2, Peng Zhang2, Yuan Chen2, Yimei Liu2, Feng Guo2, Hui Zhang2.
Abstract
BACKGROUND: Thymoma is a cancer with rare incidence, but it is a major malignancy in adult anterior mediastinum, occurring in about 40% of patients with myasthenia gravis. Because of the lack of thymic epithelial tumor cell lines, thymoma has lagged far behind other tumors in cytological studies. It is, therefore, quite necessary to establish a new thymic epithelial tumor cell line from Chinese patients to study the pathogenic mechanism and therapeutic methods.Entities:
Keywords: Cell line; myasthenia gravis; thymoma
Year: 2015 PMID: 26273358 PMCID: PMC4448491 DOI: 10.1111/1759-7714.12163
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.500
Figure 1Anterior mediastinum image of the patient and morphology feature of Thy0517 cell line in vitro. (a) The enhanced computed tomography (CT) report of the patient; (b) the picture of the original tumor; (c) hematoxylin and eosin (H&E) staining of the original tumor; (d) epithelial cells climb out after nine days of primary culture (×200); (e) morphology of the cell line at passage 30 (×200); (f) H&E staining of the cultured cell line under microscope (×200); (g,h) the growth curve of the cell line shown by cell count and MTT assay.
Primary antibodies for immunohistochemistry and immunocytochemistry
| Antibody | Type | Source | Dilution | Specificity |
|---|---|---|---|---|
| CK7 | M | ZSGB-BIO | 1:200 | Epithelial cells |
| CK5/6 | M | ZSGB-BIO | 1:200 | Epithelial cells |
| CK8/18 | M | ZSGB-BIO | 1:200 | Epithelial cells |
| CK19 | M | ZSGB-BIO | 1:200 | Epithelial cells |
| CK-Pan(AE1/3) | M | ZSGB-BIO | 1:200 | Epithelial cells |
| CD20 | R | ZSGB-BIO | 1:200 | B cells |
| CD24 | M | ZSGB-BIO | 1:200 | B cells, Multiple neoplasms |
| CD99 | R | ZSGB-BIO | 1:200 | Premature lymphocytes |
| CD117 | R | ZSGB-BIO | 1:200 | Multiple neoplasms |
| BCL-2 | R | ZSGB-BIO | 1:200 | Neoplastic cell |
| P63 | M | ZSGB-BIO | 1:200 | Epithelial cells, basal cells |
| Vimentin | R | ZSGB-BIO | 1:200 | Mesenchymal cell |
| EMA | M | ZSGB-BIO | 1:200 | Epithelial cells |
| COX2 | R | ABCAM | 1:500 | Multiple neoplasms |
| EGFR | R | ZSGB-BIO | 1:200 | Multiple epithelial neoplasms |
| TDT | M | ZSGB-BIO | 1:200 | B cell, T cell |
Polyclonal antibody. EGFR, epidermal growth factor receptor; EMA, epithelial membrane antigen; M, monoclonal (mouse); R, monoclonal (rabbit).
Figure 2The tumorigenicity test of the Thy0517 cell line in nude mice. (a) The state of the tumor after xenotransplantation of 12 weeks; (b) tumor growth of nude mice after Thy0517 cell line implantation.
Figure 3Immunocytochemistry and immunohistochemistry analysis for surface expression (high-power magnification × 20). (a) Immunocytochemical staining with positivity for CK-19; (b) immunocytochemical staining with positivity for epidermal growth factor receptor (EGFR); (c) immunocytochemical staining with positivity for CD24; (d) immunocytochemical staining with nuclear positivity for P63; (e) immunohistochemical staining with positivity for CK19 of the original tumor; (f) immunohistochemical staining with positivity for CD20 of the original tumor; (g) immunohistochemical staining with positivity for Vimentin of the original tumor; (h) immunohistochemical staining with positivity for CK19 of nude mice tumor; (i) hematoxylin and eosin staining of nude mice tumor.
Immunochemistry reactivity of Thy0517, in vitro and in vivo, including the original tumor
| Thy0517 cell lines | |||
|---|---|---|---|
| Antibody | Original tumor | ||
| CK7 | +++ | +++ | +++ |
| CK5/6 | − | − | ++ |
| CK8/18 | +++ | + | + |
| CK19 | +++ | +++ | +++ |
| CK-pan | +++ | +++ | +++ |
| CD20 | − | − | ++ |
| CD24 | ++ | +++ | + |
| CD99 | − | − | +++ |
| CD117 | − | − | − |
| BCL-2 | ++ | +++ | ++ |
| P63 | + | + | + |
| Vimentin | +++ | +++ | + |
| EMA | +++ | +++ | ++ |
| COX2 | + | + | + |
| EGFR | +++ | + | − |
| TDT | − | − | +++ |
Notes: +++, >70% positive cells; ++, 30–70% positive cells; +, <30% positive cells; −, negative reaction.
EGFR, epidermal growth factor receptor; EMA, epithelial membrane antigen.
Figure 4Chromosome analyses of Thy0517 cell line.